FDA readies for cough/cold meeting
This article was originally published in The Tan Sheet
Executive Summary
An FDA spokeswoman said Sept. 26 the agenda for the Oct. 2 meeting on OTC cough/cold products has yet to be finalized but approximately 28 parties are scheduled to make presentations. Since announcing the meeting Aug. 25, FDA has received comments from two parties, including Wayne Snodgrass, one of the petitioners whose filing led to FDA's review of pediatric cough/cold safety (1"The Tan Sheet" Oct. 22, 2007, p. 3)
You may also be interested in...
FDA Panel Narrowly Votes Against Cough/Cold Drugs For Children Up To Age 6
An FDA advisory panel decided in split votes Oct. 19 to recommend immediately that all OTC cough/cold medicines should not be used for 2-to 5-year-old children but are safe for 6- to 12-year-olds
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.